Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: Results from a large multicentre study

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 4, 2011, Pages 469-475

  Pelosi, E ^a   Penna, D ^a   Douroukas, A ^b   Bello M ^b   Amati, A ^a   Arena, V ^a   Passera, R ^b   Bisi, G ^b  

^a IRMET SpA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Bone marrow; Bone marrow biopsy; Hodgkin's disease; Non Hodgkin's lymphoma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DISEASE; CANCER STAGING; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PREDICTIVE VALUE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; BONE MARROW NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80755188031     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jost LM, Stahel RA; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol 2005;16 Suppl 1:i54-5. (Pubitemid 40872989)
2. Hiddemann W, Dreyling M, Stahel RA; ESMO Guidelines Task Force. Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol 2005;16 Suppl 1:i56-7. (Pubitemid 40872990)
3. Jost LM, Stahel RA; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma. Ann Oncol 2005;16 Suppl 1:i60-1. (Pubitemid 40872992)
4. Ng AK, Bernardo MV, Weiler E, Backstrand K, Silver B, Marcus KC et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-96. (Pubitemid 35001228)
5. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. (Pubitemid 350002966)
6. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8. (Pubitemid 350002965)
7. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidence base? Nucl Med Commun 2007;28:335-354. (Pubitemid 46569166)
8. Guermazi A, Brice P, de Kerviler EE, Ferme C, Hennequin C, Meignin V et al. Extranodal Hodgkin disease: spectrum of disease. Radiographics 2001;21:161-79. (Pubitemid 33707416)
9. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066-74. (Pubitemid 41170236)
10. Stumpe KM, Urbinelli M, Steinen HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-8. (Pubitemid 28377035)
11. Buchmann I, Reske SN. Novel imaging techniques in NHL: clinical results with PET imaging. Ann Hematol 2001;80 Suppl 3:B54-7.
12. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-34. (Pubitemid 47544887)
13. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603-9. (Pubitemid 28135606)
14. Pakos EE, Fotopoulos AD, Joannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a metaanalysis. J Nucl Med 2005;46:958-63. (Pubitemid 43733510)
15. Carr R, Barrington SF, Madan B O'Doherty MJ, Saunders CA, van der Walt J et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998,91:3340-6. (Pubitemid 28193885)
16. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S et al. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun 2006;27:11-5. (Pubitemid 44391834)
17. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007;34.60-7.
18. Muslimani AA, Farag HL, Francis S, Spiro TP, Chaudhry AA, Chan VC, Taylor HC, Daw HA. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol 2008;31:409-12.
19. Paone G, Itti E, Haioun C, Gaulard P, Dupuis J, Lin C, Meignan M. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging 2009;36:745-50.
20. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bist G. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 2008;52:9-16. (Pubitemid 351351040)
21. Levis A, Pietrasanta D, Godio L, Vitolo U, Ciravegna G, Di Vito et al. A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. Clin Lymphoma 2004;5:50-5. (Pubitemid 39136443)
22. Bremnes RM, Bremnes Y, Donnern T High-grade non-Hodgkin's lymphoma treated in northern Norway - treatment, outcome, and prognostic factors. Acta Oncol 1999;38:117-24. (Pubitemid 29119258)
23. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol1990;8:1163-72. (Pubitemid 20195626)
24. Morra E, Lazzarino M, Castello A, Inverardi D, Coci A, Pagnucco G et al. Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. Eur J Haematol 1989;42:445-53. (Pubitemid 19150280)
25. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
26. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
27. Edeiken-Monroe B, Edeiken J, Kim EE. Radiologic concepts of lymphoma of bone. Radiol Clin North Am 1990; 28:841-64. (Pubitemid 20181946)
28. Franco V, Tripodo C, Rizzo A, Stella M, Florena AM. Bone marrow biopsy in Hodgkin's lymphoma. Eur J Haematol 2004;73:149-55. (Pubitemid 39062236)
29. Gossmann A, Eich HT, Engen A, Josting A, Muller RP, Diehl V et al. CT and MR imaging in Hodgkin's disease; present and future. Eur J Haematol Suppl 2005;66:83-9. (Pubitemid 40873983)
30. Hoane BR, Shields AF, Porter BA, Shulman HM. Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood 1991;78:728-38.
31. Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. Am J Roentgenol 2005;185:711-6.
32. Shields AF, Porter BA, Churchley S, Olson DO, Appelbaum FR, Thomas ED. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. J Clin Oncol 1987;5:225-30. (Pubitemid 17021603)
33. Divgi C. Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol 2005;32(1 Suppl 1);S11-8. (Pubitemid 40409899)
34. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005;32:1406-11. (Pubitemid 41746844)
35. Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau A et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 2009:36:1813-21.